文献速递胸部肿瘤

循环肿瘤DNA在癌症患者治疗中应用的实践考量:一篇叙述性综述

Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.
PubMed 文献 · JAMA Oncol · 2022-01-01

该叙述性综述面向临床医生与相关卫生专业人员,概述循环肿瘤DNA液体活检方法的选择及其对多瘤种患者治疗与病例管理的影响,讨论影响分析有效性、临床有效性和临床实用性的多种因素,并给出推荐与实践指导。

要点

  • 液体活检在晚期肺癌中临床应用日益增多,正在识别可补充组织分析的应用场景。
  • 影响检测实用性的因素包括灵敏度与特异度、循环肿瘤DNA数量、基因 panel 大小及意义未明的克隆性造血。
  • 液体活检对无法接受活检的患者似有用,或所检突变可能比组织检测更能代表主要肿瘤负荷。

核心结论

  • 该综述发现液体活检在晚期肺癌中临床应用日益增多,正在进行的研究正在识别循环肿瘤DNA检测在广泛临床场景中补充组织分析的应用。
  • 循环肿瘤DNA技术进展迅速,在患者肿瘤诊疗旅程的多个阶段对患者、卫生从业者、卫生系统和研究者显示出潜在获益。

研究设计与样本

  • 叙述性综述,面向临床医生与相关卫生专业人员,聚焦循环肿瘤DNA液体活检方法的选择及其对多瘤种患者治疗与病例管理的影响。

主要发现

  • 当前方法包括基于聚合酶链反应的方法和使用下一代测序的方法(如基于捕获的 profiling、全外显子或基因组测序)。
  • 影响实用性的因素包括灵敏度与特异度、循环肿瘤DNA数量、检测小 panel 与 large panel 基因以及意义未明的克隆性造血。
  • 目前液体活检对无法接受活检的患者似有用,或所检突变可能比组织检测更能代表主要肿瘤负荷。
  • 其他潜在应用可能包括筛查、原发诊断、残留病灶、局部复发、治疗选择或早期治疗反应与耐药监测。

临床怎么用

  • 该综述为最佳实践提供推荐与实践指导,涉及选择最合适的液体活检检测,并聚焦循环肿瘤DNA如何影响多瘤种患者治疗与病例管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Personalized medicine based on tumor profiling and identification of actionable genomic alterations is pivotal in cancer management. Although tissue biopsy is still preferred for diagnosis, liquid biopsy of blood-based tumor analytes, such as circulating tumor DNA, is a rapidly emerging technology for tumor profiling. OBSERVATIONS: This review presents a practical overview for clinicians and allied health care professionals for selection of the most appropriate liquid biopsy assay, specifically focusing on circulating tumor DNA and how it may affect patient treatment and case management across multiple tumor types. Multiple factors influence the analytical validity, clinical validity, and clinical utility of testing. This review provides recommendations and practical guidance for best practice. Current methodologies include polymerase chain reaction-based approaches and those that use next-generation sequencing (eg, capture-based profiling, whole exome, or genome sequencing). Factors that may influence utility include sensitivity and specificity, quantity of circulating tumor DNA, detection of a small vs a large panel of genes, and clonal hematopoiesis of indeterminate potential. Currently, liquid biopsy appears useful in patients unable to undergo biopsy or where mutations detected may be more representative of the predominant tumor burden than for tissue-based assays. Other potential applications may include screening, primary diagnosis, residual disease, local recurrence, therapy selection, or early therapy response and resistance monitoring. CONCLUSIONS AND RELEVANCE: This review found that liquid biopsy is increasingly being used clinically in advanced lung cancer, and ongoing research is identifying applications of circulating tumor DNA-based testing that complement tissue analysis across a broad range of clinical settings. Circulating tumor DNA technologies are advancing quickly and are demonstrating potential benefits for patients, health care practitioners, health care systems, and researchers, at many stages of the patient oncologic journey.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Krebs MG, Malapelle U, André F, et al. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review. JAMA Oncol. 2022. PMID: 36264554. doi:10.1001/jamaoncol.2022.4457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。